tetano
Editor, Senior Moderator
Eur J Clin Pharmacol
. 2020 Aug 11;1-12.
doi: 10.1007/s00228-020-02962-5. Online ahead of print.
Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials
Can Chen[SUP] 1 [/SUP], Kunming Pan[SUP] 1 [/SUP], Bingjie Wu[SUP] 2 [/SUP], Xiaoye Li[SUP] 1 [/SUP], Zhangzhang Chen[SUP] 1 [/SUP], Qing Xu[SUP] 1 [/SUP], Xiaoyu Li[SUP] 3 [/SUP], Qianzhou Lv[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: Many concerns still exist regarding the safety of hydroxychloroquine (HCQ) in the treatment of Coronavirus Disease 2019 (COVID-19).
Objectives: The purpose of this study was to evaluate the safety of HCQ in the treatment of COVID-19 and other diseases by performing a systematic review and meta-analysis.
Methods: Randomized controlled trials (RCTs) reporting the safety of HCQ in PubMed, Embase, and Cochrane Library were retrieved starting from the establishment of the database till June 5, 2020. Literature screening, data extraction, and assessment of risk bias were performed independently by two reviewers.
Results: We identified 53 eligible studies involving 5496 patients. The meta-analysis indicated that the risk of adverse effects (AEs) in the HCQ group was significantly increased compared with that in the control group (RD 0.05, 95%CI, 0.02 to 0.07, P = 0.0002), and the difference was also statistically significant in the COVID-19 subgroup (RD 0.15, 95%CI, 0.07 to 0.23, P = 0.0002) as well as in the subgroup for other diseases (RD 0.03, 95%CI, 0.01 to 0.04, P = 0.003).
Conclusions: HCQ is associated with a high total risk of AEs compared with the placebo or no intervention in the overall population. Given the small number of COVID-19 participants included, we should be cautious regarding the conclusion stating that HCQ is linked with an increase incidence of AEs in patients with COVID-19, which we hope to confirm in the future through well-designed and larger sample size studies.
Keywords: COVID-19; Hydroxychloroquine; Randomized controlled trial; Safety; Systematic review.
. 2020 Aug 11;1-12.
doi: 10.1007/s00228-020-02962-5. Online ahead of print.
Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials
Can Chen[SUP] 1 [/SUP], Kunming Pan[SUP] 1 [/SUP], Bingjie Wu[SUP] 2 [/SUP], Xiaoye Li[SUP] 1 [/SUP], Zhangzhang Chen[SUP] 1 [/SUP], Qing Xu[SUP] 1 [/SUP], Xiaoyu Li[SUP] 3 [/SUP], Qianzhou Lv[SUP] 4 [/SUP]
Affiliations
- PMID: 32780229
- PMCID: PMC7417776
- DOI: 10.1007/s00228-020-02962-5
Abstract
Introduction: Many concerns still exist regarding the safety of hydroxychloroquine (HCQ) in the treatment of Coronavirus Disease 2019 (COVID-19).
Objectives: The purpose of this study was to evaluate the safety of HCQ in the treatment of COVID-19 and other diseases by performing a systematic review and meta-analysis.
Methods: Randomized controlled trials (RCTs) reporting the safety of HCQ in PubMed, Embase, and Cochrane Library were retrieved starting from the establishment of the database till June 5, 2020. Literature screening, data extraction, and assessment of risk bias were performed independently by two reviewers.
Results: We identified 53 eligible studies involving 5496 patients. The meta-analysis indicated that the risk of adverse effects (AEs) in the HCQ group was significantly increased compared with that in the control group (RD 0.05, 95%CI, 0.02 to 0.07, P = 0.0002), and the difference was also statistically significant in the COVID-19 subgroup (RD 0.15, 95%CI, 0.07 to 0.23, P = 0.0002) as well as in the subgroup for other diseases (RD 0.03, 95%CI, 0.01 to 0.04, P = 0.003).
Conclusions: HCQ is associated with a high total risk of AEs compared with the placebo or no intervention in the overall population. Given the small number of COVID-19 participants included, we should be cautious regarding the conclusion stating that HCQ is linked with an increase incidence of AEs in patients with COVID-19, which we hope to confirm in the future through well-designed and larger sample size studies.
Keywords: COVID-19; Hydroxychloroquine; Randomized controlled trial; Safety; Systematic review.